Results advance a high-value oncology asset towards regulatory submission and Day-1 launches across priority global markets, including the US.
Zug, Switzerland, 22nd July 2026 — Adalvo today announced positive results from its bioequivalence (BE) study for generic Ribociclib film-coated tablets. With bioequivalence now confirmed, Adalvo and its commercial partners are positioned to advance towards regulatory submission, and a day-1 launch upon expiry of applicable exclusivities and IP rights.
Developed based on the reference brand Kisqali®, Ribociclib is a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor indicated for the treatment of hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced or metastatic breast cancer. It is also approved in the adjuvant setting for patients with HR+/HER2– early breast cancer at high risk of recurrence.
Ribociclib holds the highest European Society for Medical Oncology (ESMO) clinical benefit rating of any CDK4/6 inhibitor across both early and advanced breast cancer. On the ESMO Magnitude of Clinical Benefit Scale, it holds the highest rating of any CDK4/6 inhibitor in the advanced setting, and a preliminary Grade A in early breast cancer — the highest possible score for treatments with curative intent — establishing it as a benchmark therapy in its class.
According to IQVIA, global sales of Ribociclib reached USD 4,783 million in 2025, up 57% on the prior year, reflecting consistently strong demand across all major geographies.
These results reflect Adalvo’s long-term investment in complex oncology development and its clearly defined intellectual property strategy, which together support a potential first-wave launch opportunity across priority markets. Ribociclib forms part of Adalvo’s oncology portfolio of more than 34 products, reinforcing its position as a partner of choice for differentiated, high-barrier therapies.
Adalvo’s CEO, Anil Okay, commented: “Ribociclib is a clear example of Adalvo’s growing strength in complex oncology. Achieving positive bioequivalence on a therapy of this clinical standing takes deep technical capability and precise regulatory execution. I’m proud of the team, and proud that Adalvo continues to give partners access to differentiated therapies in the areas where patients need them most.”
The successful results reflect Adalvo’s commitment to advancing high-quality, differentiated generic medicines and expanding future treatment options for patients through rigorous development and regulatory execution.
Kisqali® is a registered trademark of Novartis AG.